NeonMind Biosciences Inc (TSE:LCR)
:LCR
Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$2.31M
Enterprise ValueC$2.75M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Therapeutic Focus And Market OpportunityNeonMind’s focus on psilocybin-based mental health therapies aligns with a multi-year structural opportunity in novel psychiatric treatments. This R&D orientation targets large unmet needs and provides a durable research runway where successful clinical advances can translate into long-term licensing and commercialization optionality.
Asset-Light Licensing Business ModelA business model built around developing IP and licensing reduces the need for heavy manufacturing or commercialization capex. If clinical programs progress, licensing or partnership deals can scale revenue without proportional capital intensity, preserving upside while limiting long-term fixed-cost commitments.
Moderate Absolute Debt LoadAbsolute debt levels are modest in nominal terms, which lessens immediate leverage strain relative to high-debt peers. This gives the company some flexibility to secure short-term financing or partnerships to advance programs, provided it addresses persistent losses; manageable nominal debt is a stabilizing structural factor.
Bears Say
No Recurring Revenue BaseThe absence of recurring revenue across multiple years is a core structural weakness. Without product sales or steady licensing income, the company cannot internally fund development, validate commercial demand, or demonstrate scalable revenue drivers, increasing reliance on external capital over the medium term.
Negative Shareholders' EquityPersistent negative equity weakens financial flexibility and elevates solvency risk. This structural balance-sheet impairment can constrain access to credit, raise financing costs, and increase the likelihood of dilutive capital raises or distressed transactions if operational performance does not improve.
Sustained Cash Burn And Operating LossesConsistent negative operating and free cash flow force ongoing external funding to sustain trials and operations. Over a 2–6 month horizon this heightens execution and dilution risk, as management must secure financing before clinical or licensing milestones generate internal cash flow.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$2.31M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 45 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---